类固醇和生物活性分子合物:改善疾病管理中的治疗方法
Anna Kawka1, Hanna Koenig1, Tomasz Pospieszny1
1Department of Bioactive Products, Faculty of Chemistry, Adam Mickiewicz University, Uniwersytetu Poznańskiego 8 Street, 61-614 Poznań, Poland.
Bioorganic chemistry
|November 7, 2024
概括
类固醇合物,将类固醇与天然分子结合在一起,提供增强的药物特性和多种治疗用途. 这些化合物改善药物输送,减少副作用,并显示出治疗各种疾病的潜力.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 通过将类固醇与氨基酸或碳水化合物等生物活性分子结合而形成的类固醇合物,因其治疗潜力而受到关注.
- 这些合物比原始类固醇化合物具有优势,包括改善的药理动力学特征,增强的标特异性和最小化的不良影响.
研究的目的:
- 审查类固醇结合物的意义和广泛的治疗应用.
- 突出类固醇结合体在药物输送系统中的作用,以及它们对医疗治疗进行革命的潜力.
主要方法:
- 关于类固醇结合物的科学出版物的文献综述.
- 对研究的分析,重点是药理动力学特性,标特异性和临床实用性.
- 检查药物输送,疾病治疗和作为药物载体的应用.
主要成果:
- 与母体类固醇相比,类固醇合物显示出更好的生物利用性,药理动力学和向特异性.
- 它们在药物输送系统中具有多功能,允许控制释放和生物可用性调节.
- 应用范围包括炎症性,神经退行性,荷尔蒙性疾病,癌症治疗和传染病.
结论:
- 类固醇合物在现代医学中至关重要,提供了增强的治疗效益和改善患者的治疗结果.
- 它们的潜力扩展到开发先进的药物载体和水凝器,用于创新的医疗解决方案.
更多相关视频
相关概念视频
Prodrugs
2.5K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.5K
Principles of Drug Action
5.9K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
5.9K
Drug Biotransformation: Overview
2.3K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.3K
Phase II Conjugation Reactions: Overview
166
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
166
Drug Metabolism: Phase II Reactions
3.7K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.7K
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K


